WHAT'S NEW IN METASTATIC COLON CANCER TREATMENT?

Karabulut S., Karabulut M., Tastekin D.

JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI, cilt.84, sa.3, ss.425-429, 2021 (ESCI) identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 84 Sayı: 3
  • Basım Tarihi: 2021
  • Doi Numarası: 10.26650/iuitfd.2020.0086
  • Dergi Adı: JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESI DERGISI
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.425-429
  • Anahtar Kelimeler: Metastatic colon cancer, treatment, innovations, FOLFOXIRI PLUS BEVACIZUMAB, WILD-TYPE KRAS, COLORECTAL-CANCER, 1ST-LINE TREATMENT, OPEN-LABEL, TRIAL, PANITUMUMAB, THERAPY, TAS-102, BENEFIT
  • İstanbul Üniversitesi Adresli: Evet

Özet

In this review, we present the current innovations in the field of metastatic colon cancer (mCRC). Tumor placement is important in the mCRC treatment decision, and KRAS, NRAS, BRAF mutation analysis is performed in terms of prognosis/predictivity. Immunotherapy is the treatment option in patients with 5-6% and dMMR/MSI. The concept of NeoRAS will become more on the agenda in the near future as high-level evidence becomes available. Molecular evaluations have become extremely important in terms of prognosis and predictions in the treatment of mCRC, as in many tumors today.